ESMO World Congress on Gastrointestinal Cancer 2019

Topics

• Bile Duct Cancer
  • New agents/strategies on the horizon in bile duct cancer
  • Molecular alterations in bile duct cancer
• Cancer of the Pancreas
  • Are we making progress in surgery of the pancreas?
  • Genetics and molecular alterations in pancreatic cancer
  • Improving the outcomes of patients with metastatic pancreatic cancer
  • Adjuvant and neo-adjuvant treatment of pancreatic cancer in resectable pancreatic cancer
• New Concepts in Clinical Trials
  • Tumor agnostic trials and approaches
  • Clinical interpretation and validity of clinical trials: When do they become practice-changing?
  • Studying biosimilars: What is needed and what is the role of biosimilars?
  • Studying value and health economics
• Meet the Expert Presentations
  • Advances in surgery of rectal cancer
  • New endoscopic screening tools: NBI, chromoendoscopy - How do they help us?
  • Progress in anal cancer
  • Teaching on new evolutions in radiation oncology
  • How to classify NET`s and NEC`s?
  • Carcinoma of unknown origin
  • ESMO Session: Focus on young medical oncologists
• Relevant pathways in GI cancer: how relevant and how to approach them?
  • The FGF pathway
  • The HER-2 pathway
  • NGS testing for all patients with GI cancers?
  • Fusions in GI cancers
• Esophageal and Gastric Cancers
  • Barrett esophagus: Role of advanced endoscopy in the diagnosis and treatment
  • Unraveling the molecular taxonomy in esophageal and gastric cancer
  • Definitive CRT or neoadjuvant therapy followed by surgery in esophageal cancer
  • Management of squamous cell cancer for the esophagus
  • Surgery in oligometastastic gastric cancer?
  • Locally advanced GE junction cancer: CRT or perioperative CT
  • Metastatic gastric cancer: New targeted agents in metastatic gastric cancer
  • Metastatic gastric cancer: Where are we with checkpoint inhibitors in gastric cancer?
• Expert Highlights: What is New in This Disease in 2019?
  • What is new in GIST?
  • What is new in NET?
  • What is new in bile duct cancer?
  • What is new in anal cancer?
  • Genetic testing for familial and hereditary colorectal cancer
  • Prevention and Screening of Colon Cancer
  • Will chemoprevention become a reality?
  • Screening for colon cancer: What has been achieved in 2019 & new prospects?
• Hepatocellular Carcinoma
  • Locoregional treatment for HCC
  • How to integrate new agents in HCC?
  • Multidisciplinary tumor board on HCC
• Molecular Biology in CRC
  • Current status and perspectives on liquid biopsies in GI cancer
  • How to approach the patient with a BRAF mutant tumor?
  • Practical implications of the molecular and immunologic classifications in CRC
  • Is circulating DNA relevant in stage II colon cancer?
  • Is broad NGS testing useful in my patients with metastatic colorectal cancer?
• Multimodality Therapy for Rectal Cancer
  • Rectal cancer after neoadjuvant therapy with complete clinical response: Surgery or watchful waiting
  • Imaging in rectal cancer
  • Adjuvant chemotherapy in rectal cancer or introduce more neo-adjuvant chemotherapy
  • New evolutions and ideas in surgery
  • The strategy in synchronous liver metastases of rectal cancer
• Multidisciplinary Tumor Boards
  • The challenging patient with HCC
  • Molecular and hereditary tumor board
  • The challenging patient with colorectal cancer
• Key Note Lectures
  • Novel immune oncology mechanisms and approaches in GI cancers: where are we?
  • The microbiome in GI cancers
  • Should DPD deficiency be searched before starting 5FU?
  • What to do with a malignant colon polyp?
  • How to look for minimal residual disease?
  • Relevant drug interactions in GI Oncology
• Colorectal Cancer
  • Chemorefractory colorectal cancer
  • Updates on treatment algorithms in metastatic CRC in 2019
  • Can we refine the selection for adjuvant treatment in stage II colon cancer?
  • Can we refine the selection for adjuvant treatment in stage III colon cancer?
• Immune Mechanisms and Immune Therapy in GI Cancer
  • Biomarkers for check-point inhibitors in GI cancer
  • How to improve the results with IO agents in MSI GI cancer?
  • Are we making progress with IO in pancreatic cancer?
  • How can we increase the immunogenicity in MSS CRC?
  • The link between the immune microenvironement and outcome in colorectal cancer
• Clinical Updates
  • Liver resection of liver metastases
  • When and how to select for debulking and HIPEC in peritoneal carcinomatosis?

Who should Attend

• Medical Oncologists
• Physicians
• Pathologists
• Radiation Oncologists
• Gastroenterologists
• Hepatologists
• Clinical Researchers
• Surgeons